Image

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Exploring Inotuzumab Ozogamicin for young patients with specific blood cancers.

Recruiting
1-21 years
All
Phase 2

This study looks at inotuzumab ozogamicin, a special medicine for young patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia. These are types of blood cancer that have returned or don’t respond to regular treatment. Inotuzumab ozogamicin is a monoclonal antibody, which is like a special marker that attaches to cancer cells with a CD22 marker. It carries a toxin to kill the cancer cells.

In the study, patients are divided into two groups. The first group (Cohort I) will receive inotuzumab ozogamicin through an IV (a tube into a vein) for 60 minutes on certain days, up to 6 cycles. The second group (Cohort II) gets inotuzumab ozogamicin plus other drugs. Patients will have tests like blood tests and scans during the study.

Key Points:

  • The study could last for several months with cycles repeating every 28-42 days.
  • Regular visits and tests are required to monitor the patient's health and cancer progression.
  • There are risks, such as side effects from the drugs, which the study aims to understand better.
Study details
    Recurrent B Acute Lymphoblastic Leukemia
    Recurrent B Lymphoblastic Lymphoma
    Refractory B Acute Lymphoblastic Leukemia
    Refractory B Lymphoblastic Lymphoma

NCT02981628

Children's Oncology Group

14 June 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Race
Ethnicity
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.